SEC Form 4 · accession 0001209191-17-037928
VERTEX PHARMACEUTICALS INC / MA · VRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David Altshuler
Officer — EVP, Global Research and CSO
Period of report
Jun 5, 2017
Accepted (ET)
Jun 5, 2017 · 6:10 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 5, 2017 | M | 7,500 | $72.14 | A | 113,511 | D | |
| Common Stock | Jun 5, 2017 | S | 7,500 | $130.00 | D | 106,011 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $72.14 | Jun 5, 2017 | M | 7,500 | D | — | May 31, 2024 | Common Stock | 7,500 | 0 | D |
Explanation of responses
- F1Transaction made pursuant to Mr. Altshuler's company approved trading plan under Rule 10b5-1.
- F2Fully vested.